Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 1.7% - Should You Sell?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report)'s stock price traded down 1.7% during trading on Monday . The stock traded as low as $4.18 and last traded at $4.08. 3,152 shares changed hands during trading, a decline of 81% from the average session volume of 16,604 shares. The stock had previously closed at $4.15.

Analyst Upgrades and Downgrades

Separately, Craig Hallum assumed coverage on Eupraxia Pharmaceuticals in a report on Friday, February 21st. They set a "buy" rating and a $12.00 target price on the stock.

Eupraxia Pharmaceuticals Price Performance

The company has a market cap of $142.41 million and a P/E ratio of -5.55. The company has a fifty day simple moving average of $3.44 and a 200-day simple moving average of $3.08.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of EPRX. Millennium Management LLC bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at $31,000. Raymond James Financial Inc. bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at $37,000. Finally, Bank of Montreal Can increased its holdings in shares of Eupraxia Pharmaceuticals by 15.2% in the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock valued at $178,000 after buying an additional 7,500 shares in the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.